Importance of asparagine-381 and arginine-487 for substrate recognition in CYP4Z1.
Breast cancer
CYP4Z1
Molecular modeling
Mutational studies
Substrate recognition
Journal
Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
11
12
2019
accepted:
06
02
2020
pubmed:
12
2
2020
medline:
1
9
2020
entrez:
12
2
2020
Statut:
ppublish
Résumé
The human cytochrome P450 enzyme CYP4Z1 remains an understudied enzyme despite its association with poor prognosis and overexpression in breast cancer. Hence, CYP4Z1 has previously been suggested as an anti-breast cancer target. In the present study we employed extended mutation analysis to increase our understanding of the substrate binding mode of this enzyme. In a combined in vitro and in silico approach we show for the first time that residue Arg487 plays an important role in substrate recognition and binding of CYP4Z1. Using a large array of recombinant CYP4Z1 mutants we show that, apart from Asn381, all other postulated binding residues only play an auxiliary role in substrate recognition and binding. Different substrate interaction motifs were identified via dynamic pharmacophores (dynophores) and their impact on catalytically competent substrate binding was classified. These new insights on the substrate recognition and binding mode represent an important step towards the rational design of CYP4Z1 prodrugs and guide further investigations into the so far poorly understood physiological role of CYP4Z1.
Identifiants
pubmed: 32044355
pii: S0006-2952(20)30071-X
doi: 10.1016/j.bcp.2020.113850
pii:
doi:
Substances chimiques
Asparagine
7006-34-0
Arginine
94ZLA3W45F
CYP4Z1 protein, human
EC 1.14.14.1
Cytochrome P450 Family 4
EC 1.14.14.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113850Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare no conflict of interest.